Abstract
The implantable cardioverter-defibrillator (ICD) is an essential lifesaving device implanted worldwide for the prevention of sudden cardiac death (SCD). Several clinical trials have demonstrated the efficacy of ICDs in both primary and secondary prevention cohorts over the last two and a half decades.1–5 Transvenous implantable cardioverter-defibrillators (TV-ICDs) have traditionally been implanted for such purposes. However, the TV-ICD system has considerable limitations and is associated with short- and long-term adverse events related to the endovascular lead.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
